ENDEAVOR trial: Carfilzomib and dexamethasone for relapsed multiple myeloma

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of the multicenter, open-label, randomized, phase 3 ENDEAVOR trial of carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed multiple myeloma.

Share this video  
11th June 2015